Kazia Therapeutics Limited Launches Phase 1b Trial of Paxalisib in Advanced Breast Cancer, Dosing First Patient

Reuters

06/05

<a href="https://laohu8.com/S/KZIA">Kazia Therapeutics Limited</a> Launches Phase 1b Trial of Paxalisib in Advanced Breast Cancer, Dosing First Patient

Kazia Therapeutics Limited has announced the initiation of a Phase 1b clinical trial for its drug paxalisib in patients with advanced breast cancer. The trial, sponsored by Kazia, will explore the effectiveness of paxalisib, a dual PI3K/mTOR inhibitor, when used in combination with either olaparib or pembrolizumab. This multi-center, open-label, randomized study aims to assess the safety, tolerability, and preliminary efficacy of these treatment combinations. The trial will also conduct deep biomarker profiling to aid future development and evaluate early signals of clinical activity. This marks a significant step for Kazia as it extends the application of paxalisib beyond brain cancer to other solid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: NY03762) on June 05, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2541077027"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541077027\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541077027?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541077027","market":"us","top_or_hot":-1,"title":"Kazia Therapeutics Limited Launches Phase 1b Trial of Paxalisib in Advanced Breast Cancer, Dosing First Patient","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KZIA\">Kazia Therapeutics Limited</a> Launches Phase 1b Trial of Paxalisib in Advanced Breast Cancer, Dosing First Patient\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NVGNF\">Kazia Therapeutics Limited</a> has announced the initiation of a Phase 1b clinical trial for its drug paxalisib in patients with advanced breast cancer. The trial, sponsored by Kazia, will explore the effectiveness of paxalisib, a dual PI3K/mTOR inhibitor, when used in combination with either olaparib or pembrolizumab. This multi-center, open-label, randomized study aims to assess the safety, tolerability, and preliminary efficacy of these treatment combinations. The trial will also conduct deep biomarker profiling to aid future development and evaluate early signals of clinical activity. This marks a significant step for Kazia as it extends the application of paxalisib beyond brain cancer to other solid tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KZA.AU\">Kazia Therapeutics</a> Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: NY03762) on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kazia Therapeutics Limited Launches Phase 1b Trial of Paxalisib in Advanced Breast Cancer, Dosing First Patient</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKazia Therapeutics Limited Launches Phase 1b Trial of Paxalisib in Advanced Breast Cancer, Dosing First Patient\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-05 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KZIA\">Kazia Therapeutics Limited</a> Launches Phase 1b Trial of Paxalisib in Advanced Breast Cancer, Dosing First Patient\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NVGNF\">Kazia Therapeutics Limited</a> has announced the initiation of a Phase 1b clinical trial for its drug paxalisib in patients with advanced breast cancer. The trial, sponsored by Kazia, will explore the effectiveness of paxalisib, a dual PI3K/mTOR inhibitor, when used in combination with either olaparib or pembrolizumab. This multi-center, open-label, randomized study aims to assess the safety, tolerability, and preliminary efficacy of these treatment combinations. The trial will also conduct deep biomarker profiling to aid future development and evaluate early signals of clinical activity. This marks a significant step for Kazia as it extends the application of paxalisib beyond brain cancer to other solid tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KZA.AU\">Kazia Therapeutics</a> Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: NY03762) on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KZIA","symbol_name":"Kazia Therapeutics Limited","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDLbQRBFL:1","article_id":"2541077027","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541077027","pubTimestamp":1749124887,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kazia Therapeutics Limited has announced the initiation of a Phase 1b clinical trial for its drug paxalisib in patients with advanced breast cancer. The trial, sponsored by Kazia, will explore the effectiveness of paxalisib, a dual PI3K/mTOR inhibitor, when used in combination with either olaparib or pembrolizumab. This multi-center, open-label, randomized study aims to assess the safety, tolerability, and preliminary efficacy of these treatment combinations. The trial will also conduct deep biomarker profiling to aid future development and evaluate early signals of clinical activity. This marks a significant step for Kazia as it extends the application of paxalisib beyond brain cancer to other solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KZIA":"Kazia Therapeutics Limited","BK4139":"生物科技"},"translate_title":"Kazia Therapeutics Limited启动Paxalisib治疗晚期乳腺癌的1b期试验，为首例患者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KZIA":0.9},"content_text":"Kazia Therapeutics Limited Launches Phase 1b Trial of Paxalisib in Advanced Breast Cancer, Dosing First Patient\n    \n\nKazia Therapeutics Limited has announced the initiation of a Phase 1b clinical trial for its drug paxalisib in patients with advanced breast cancer. The trial, sponsored by Kazia, will explore the effectiveness of paxalisib, a dual PI3K/mTOR inhibitor, when used in combination with either olaparib or pembrolizumab. This multi-center, open-label, randomized study aims to assess the safety, tolerability, and preliminary efficacy of these treatment combinations. The trial will also conduct deep biomarker profiling to aid future development and evaluate early signals of clinical activity. This marks a significant step for Kazia as it extends the application of paxalisib beyond brain cancer to other solid tumors.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: NY03762) on June 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}